Skin cancer in organ transplant recipients - Where do we stand today?

American Journal of Transplantation

Volumn 8, Issue 11, 2008, Pages 2192-2198

  Ulrich, C ^a   Kanitakis, J ^b   Stockfleth, E ^a   Euvrard, S ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Immunosuppression; mTOR inhibitors; Organ transplantation; Skin cancer prophylaxis; Skin cancer treatment; Sun screen

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; DICLOFENAC; EVEROLIMUS; FLUOROURACIL; IMIQUIMOD; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RETINOID; SUNSCREEN;

BASAL CELL CARCINOMA; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; NONHUMAN; ORGAN TRANSPLANTATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECIPIENT; SHORT SURVEY; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; DERMATOLOGY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KERATOSIS; MEDICAL ONCOLOGY; ORGAN TRANSPLANTATION; RISK; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 53749099885     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02386.x     Document Type: Short Survey

References (34)

1. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003 348 : 1681 1691.
2. Ulrich C, Schmook T, Sachse M, Sterry W, Stockfleth E. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg 2004 30 : 622 627.
3. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004 4 : 905 913.
4. Ramsay HM, Reece SM, Fryere AA, Smith AG, Harden PN. Seven-year prospective study of nonmelanoma skin cancer incidence in UK renal transplant recipients. Transplantation 2007 84 : 437 439.
5. Bordea C, Wojnarowska F, Millard PR, Doll H, Welsh K, Morris PJ. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004 77 : 574 579.
6. Fortina AB, Caforio AL, Piaserico S et al. Skin cancer in heart transplant recipients: Frequency and risk factor analysis. J Heart Lung Transplant 2000 19 : 249 255.
7. Otley C, Cherikh WS, Salsche SJ, McBride MA, Christenson LJ, Kauffman HM. Skin cancer in organ transplant recipients: Effect of pretransplant end-organ disease. J Am Acad Dermatol 2005 53 : 783 790.
8. Euvrard S, Kanitakis J. Skin cancers after liver transplantation: What to do? J Hepatol 2006 44 : 27 32.
9. Bouwes-Bavinck JN, Euvrard S, Naldi L et al. Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: A case-control study in The Netherlands, United Kingdom, Germany, France and Italy. J Invest Dermatol 2007 127 : 1647 1656.
10. Euvrard S, Kanitakis J, Decullier E et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006 81 : 1093 1100.
11. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens. Lancet 1998 351 : 623 628.
12. Laing ME, Kay E, Conlon P, Murphy GM. Genetic factors associated with skin cancer in renal transplant patients. Photodermatol Photoimmunol Photomed 2007 23 : 62 67.
13. De Graaf YGL, Rebel H, Elghalbzouri A et al. More epidermal p53 patches adjacent to skin carcinomas in renal transplant recipients than in immunocompetent patients: The role of azathioprine. Exp Dermatol 2008 17 : 349 355.
14. Kauffman HM, Cherikh WS, Cheng U et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005 80 : 883 889.
15. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004 77 : 1777 1782.
16. Otley CC, Maragh SL. Reduction of immunosuppression for transplant associated skin cancer: Rationale and evidence of efficacy. Dermatol Surg 2005 31 : 163 168.
17. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006 17 : 581 589.
18. O'Donovan P, Perret CM, Zhang X et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005 309 : 1871 1874.
19. Duncan FJ, Wulff BC, Tober KL et al. Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. Am J Transplant 2007 7 : 2693 2703.
20. Wulff BC, Kusewitt DF, VanBuskirk AM et al. Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice even with co-administration of cyclosporine. J Invest Dermatol 8 May 2008 (Epub ahead of print).
21. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004 18 : 446 449.
22. Levi Z, Hazazi R, Kedar-Barnes I et al. Switching from Tacrolimus to Sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre Syndrome. Am J Transplant 2007 7 : 476 479.
23. Lebbé C, Euvrard S, Barrou B et al. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant 2006 6 : 2164 2168.
24. Tessmer CS, Magalhaes LV, Keitel E et al. Conversion to sirolimus in renal transplant recipients with skin cancer. Transplantation 2006 82 : 1792 1793.
25. Fernandez A, Marcen R, Pascual J et al. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transplant Proc 2006 38 : 2453 2455.
26. Stasko T, Brown MD, Carucci J et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 2004 30 : 642 650.
27. Ulrich C, Hackethal M, Ulrich M et al. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: A series of six cases. Br J Dermatol 2007 156 S3 : 40 42.
28. Ulrich, Bichel J, Euvrard S et al. Topical immunomodulation under systemic immunosuppression: Results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant recipients. Br J Dermatol 2007 157S2 : 25 31.
29. Perrett CM, McGregor JM, Warwick J et al. Treatment of post-transplant premalignant skin disease: A randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 2007 156 : 320 328.
30. De Graaf YG, Kennedy C, Wolterbeek R, Collen AF, Willemze R, Bouwes Bavinck JN. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: Results of a randomized-controlled trial. J Invest Dermatol 2006 126 : 569 574.
31. De Graaf YG, Euvrard S, Bouwes Bavinck JN. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg 2004 30 : 656 661.
32. Mahé E, Morelon E, Lechaton S et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005 79 : 476 482.
33. Ulrich C, Degen A, Patel MJ et al. Sunscreens in organ transplant patients. Nephrol Dial Transplant 2008 23 : 1805 1808.
34. Ismail F, Mitchell L, Casabonne D et al. Specialist dermatology clinics for organ transplant recipients significantly improve photoprotection and levels of skin cancer awareness. Br J Dermatol 2006 155 : 916 925.